P/B
72,5
Nuvectis Pharma
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
$658.8M
Market Cap • 9/25/2026
2020
(6 years)
Founded
2022
(4 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
0,4
EPS
—
Market Cap
Market Cap
658,8M
EV
636,6M
EV/Revenue
0
EV/EBITDA
-22,1
EV/EBIT
-22,1
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-2,3%
Total Yield
-2,3%
Payout
0%
Retained Earnings
-112,8M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
0%
% Goodwill
0%
ROE
—
ROIC
—
Leverage
N.D./EBITDA
0,8
Debt/Equity
0%
Current Ratio
1,7
Quick Ratio
1,7
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!